Description
Gemcitabin Medak Powder for Infusions 1000 mg Vial №1
Composition
Gemcitabin Medak powder for infusions 1000 mg vial №1 contains Gemcitabine hydrochloride as the active ingredient.
Mechanism of Action
Gemcitabine hydrochloride, the active ingredient in Gemcitabin Medak, exerts its pharmacological effects by disrupting the synthesis of DNA and RNA in cancer cells, thereby inhibiting their growth and proliferation.
Pharmacological Properties
Gemcitabin Medak exhibits cytotoxic activity against a wide range of cancer types by interfering with nucleic acid metabolism, leading to cell death.
Indications for Use
Gemcitabin Medak is indicated for the treatment of pancreatic cancer, breast cancer, and non-small cell lung cancer among other malignancies.
Contraindications
Use of Gemcitabin Medak is contraindicated in individuals with a history of hypersensitivity reactions to gemcitabine or any other components of the product.
Side Effects
Common side effects associated with Gemcitabin Medak include nausea, vomiting, myelosuppression, and flu-like symptoms. Patients may also experience peripheral edema and skin rashes.
Usage Instructions
Gemcitabin Medak should be administered via intravenous infusion by a healthcare professional trained in oncology. Dosage and administration schedule should be individualized based on the patient’s condition and response to treatment.
Benefits Compared to Analogues
Gemcitabin Medak offers a favorable safety profile and demonstrated efficacy in various cancer types, with a well-established role in the management of advanced malignancies.
Suitable Patient Groups
Gemcitabin Medak can be used in adult patients across different age groups, with dosing adjustments made based on individual patient characteristics and comorbidities.
Storage and Shelf Life
Store Gemcitabin Medak as per the manufacturer’s instructions, in a cool and dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product beyond this date.
Packaging Description
Gemcitabin Medak is available in single-dose vials containing 1000 mg of Gemcitabine hydrochloride powder for reconstitution prior to intravenous administration.
Clinical Evidence and Proven Effectiveness
Gemcitabin Medak has been extensively studied in clinical trials, demonstrating significant improvements in overall survival and quality of life in cancer patients. Research supports its role as a cornerstone in the treatment of various malignancies.
Additional Information
Patients receiving Gemcitabin Medak should be closely monitored for adverse reactions and managed promptly. It is essential to adhere to proper handling and administration protocols to ensure treatment safety and efficacy.
- Always adhere to the prescribed Gemcitabin Medak dosage and administration regimen.
- Inform your healthcare provider about all medications and supplements before starting Gemcitabin Medak therapy.
- Promptly report any side effects or concerns related to Gemcitabin Medak treatment to your healthcare provider.
